11.30
+1.805(+19.01%)
Currency In USD
| Previous Close | 9.49 |
| Open | 9.93 |
| Day High | 11.71 |
| Day Low | 9.63 |
| 52-Week High | 21.95 |
| 52-Week Low | 4.5 |
| Volume | 222,481 |
| Average Volume | 51,622 |
| Market Cap | 45.7M |
| PE | -0.52 |
| EPS | -21.61 |
| Moving Average 50 Days | 7.04 |
| Moving Average 200 Days | 9.2 |
| Change | 1.81 |
If you invested $1000 in FibroGen, Inc. (FGEN) 10 years ago, it would be worth $18.25 as of August 18, 2025 at a share price of $11.3. Whereas If you bought $1000 worth of FibroGen, Inc. (FGEN) shares 5 years ago, it would be worth $10.18 as of August 18, 2025 at a share price of $11.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
GlobeNewswire Inc.
10 hours ago
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen Inter
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
GlobeNewswire Inc.
Aug 07, 2025 11:00 AM GMT
FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) tran
FibroGen to Report Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 04, 2025 8:02 PM GMT
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eas